Clinical trial
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
NCT00117936 · CardioVascular BioTherapeutics, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00117936 |
|---|---|
| Title | Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease |
| Official title | Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study |
| Lead sponsor | CardioVascular BioTherapeutics, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis |
| Intervention type | Combination Product |
| Interventions | Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose, Placebo |
| Enrollment | 150 |
| Start date | Mar 1, 2020 |
| Primary completion | Mar 1, 2022 |
| Completion | Mar 1, 2023 |
| First posted | Jul 11, 2005 |
| Last update posted | Nov 1, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: